RepliCel Life Sciences Inc. | |
Stock Exchange | Other OTC |
EPS |
$0.1 |
Market Cap |
$6.02 M |
Shares Outstanding |
21.44 M |
Public Float |
20.19 M |
RepliCel Life Sciences Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
21.44 M |
Public Float |
20.19 M |
RepliCel Life Sciences Inc. | |
Stock Exchange | Toronto Ventures Stock Exchange |
EPS |
CAD0.13 |
Market Cap |
CAD7.86 M |
Shares Outstanding |
17.25 M |
Public Float |
8.62 M |
Address |
570 Granville Street Vancouver British Columbia V6C 3P1 Canada |
Employees | - |
Website | http://www.replicel.com |
Updated | 07/08/2019 |
RepliCel Life Sciences, Inc. is a regenerative medicine company, which focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Its products includes RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada. |